Business context and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023—not a filing for Bio Green Med Solution, Inc. Cyclacel is a clinical-stage biopharmaceutical company developing cancer candidates fadraciclib and plogosertib. It reported no revenue in the quarter.
Fadraciclib studies were ongoing; 24 patients had been treated in one solid-tumor/lymphoma study. In the plogosertib study, nine patients had been treated at the first three dose levels, with no dose-limiting toxicities observed. These are early-stage clinical updates, not efficacy conclusions.
Key financial metrics
Unless otherwise stated, amounts are in millions of U.S. dollars; expense and cash-flow figures are for the three months ended March 31.
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.674 | $4.954 |
| General and administrative expense | $1.645 | $1.605 |
| Operating loss | $(7.319) | $(6.559) |
| Net loss | $(5.804) | $(4.108) |
| Net loss applicable to common shareholders | $(5.854) | $(4.158) |
| Basic and diluted loss per share | $(0.47) | $(0.42) |
| Net cash used in operating activities | $(6.861) | $(6.775) |
At March 31, 2023, cash and cash equivalents were $11.435 million, versus $18.345 million at December 31, 2022. Total assets were $22.060 million and total liabilities were $7.418 million. The balance sheet shows current assets of $18.974 million and current liabilities of $7.338 million. The company had $2.916 million of clinical-trial deposits and $0.080 million of lease liability; the filing reports no conventional borrowings or debt financing outstanding. Working capital is stated as $11.636 million in the balance-sheet figures, while MD&A separately reports $11.636 million using current assets of $19.676 million and current liabilities of $8.040 million; the different classification basis is not clearly explained in the supplied text.
No meaningful revenue or profit margin was reported because the company had no revenue and incurred operating losses. Q1 cash used in investing activities was $0.006 million; the $0.050 million financing cash outflow reflected a preferred-stock dividend payment. Cash declined by $6.910 million during the quarter.
Material changes versus the prior comparable period
- R&D expense rose 15% to $5.674 million, with spending increases in both fadraciclib and plogosertib programs.
- G&A expense increased 2% to $1.645 million.
- Net loss widened by $1.696 million. Other income declined to $0.195 million from $1.313 million, principally reflecting lower income associated with the Thermo Fisher asset-purchase agreement; Q1 2023 other income also included recovery of clinical manufacturing costs.
- Weighted-average common shares increased to 12.539 million from 9.993 million, and loss per share increased to $0.47 from $0.42.
- Cash and cash equivalents fell from $29.639 million at March 31, 2022 to $11.435 million at March 31, 2023.
Outlook, risks and unusual items
- Going concern: Management said $11.4 million of quarter-end cash, together with $4.7 million of U.K. R&D tax credits received in April, was expected to fund operations through the end of 2023. The filing nevertheless concludes that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from issuance, given continuing losses, negative operating cash flow and dependence on future financing.
- Funding risk: The company is seeking additional capital through equity or debt financings or partnerships, but says there is no assurance funding will be available on acceptable terms or at all. A shortfall could delay, reduce or end clinical trials or other R&D programs.
- Management outlook: Cyclacel anticipated lower full-year 2023 R&D expense than in 2022 as programs progress, and lower G&A expense due to efforts to reduce professional costs. It did not provide specific financial guidance amounts.
- Potential rescission rights: Cyclacel reclassified 3,117,100 shares sold after expiration of a shelf registration statement, representing approximately $4.494 million, outside stockholders’ equity because certain purchasers may have rescission rights. No claims or demands had been made as of March 31, 2023. The shares remained treated as issued and outstanding for financial reporting.
- Other risks: Management cited possible effects of foreign-exchange movements, uncertainty around future royalty income and U.K. R&D tax-credit eligibility, and potential impacts of supply-chain challenges, COVID-19 and geopolitical turmoil on clinical trials and financing.
- The filing reported no legal proceedings, no material changes to previously disclosed risk factors and effective disclosure controls as of March 31, 2023.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is for Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Track cash use, the timing of funding needs and whether new financing or partnerships are secured; the stated cash runway only extends through year-end 2023.
- Monitor the potential rescission rights related to the $4.494 million share sale and the status of any claims or resolution.
- Review clinical-trial progress, safety and efficacy data for fadraciclib and plogosertib; the reported patient counts and dose-escalation observations do not establish efficacy.
- Reconcile the working-capital presentation and classification differences between the balance sheet and MD&A.
- Assess the sustainability of U.K. tax-credit receipts and uncertain royalty or other income.